Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Moderna (NASDAQ:MRNA) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025. The company will host a live conference call and webcast at 8:00 a.m. ET to present the results and provide a corporate update.
Investors can access the live webcast through the 'Events and Presentations' section on Moderna's investor website. The archived version will be available approximately two hours after the conference call and remain accessible for one year.
Moderna (NASDAQ:MRNA) ha programmato l'annuncio dei suoi risultati finanziari per il primo trimestre del 2025 per giovedì 1 maggio 2025. L'azienda ospiterà una conferenza telefonica in diretta e un webcast alle 8:00 a.m. ET per presentare i risultati e fornire un aggiornamento aziendale.
Gli investitori possono accedere al webcast dal vivo tramite la sezione 'Eventi e Presentazioni' sul sito web per investitori di Moderna. La versione archiviata sarà disponibile circa due ore dopo la conferenza telefonica e rimarrà accessibile per un anno.
Moderna (NASDAQ:MRNA) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el jueves 1 de mayo de 2025. La compañía llevará a cabo una conferencia telefónica en vivo y una transmisión por webcast a las 8:00 a.m. ET para presentar los resultados y proporcionar una actualización corporativa.
Los inversores pueden acceder a la transmisión en vivo a través de la sección 'Eventos y Presentaciones' en el sitio web para inversores de Moderna. La versión archivada estará disponible aproximadamente dos horas después de la conferencia telefónica y permanecerá accesible durante un año.
모더나 (NASDAQ:MRNA)는 2025년 1분기 재무 결과 발표를 2025년 5월 1일 목요일로 예정했습니다. 회사는 오전 8시(동부 표준시)에 결과를 발표하고 기업 업데이트를 제공하기 위해 실시간 전화 회의 및 웹캐스트를 진행합니다.
투자자들은 모더나의 투자자 웹사이트의 '이벤트 및 발표' 섹션을 통해 실시간 웹캐스트에 접근할 수 있습니다. 아카이브 버전은 전화 회의 후 약 2시간 후에 제공되며 1년 동안 접근 가능합니다.
Moderna (NASDAQ:MRNA) a programmé l'annonce de ses résultats financiers pour le premier trimestre 2025 pour le jeudi 1er mai 2025. L'entreprise organisera une conférence téléphonique en direct et un webcast à 8h00 (heure de l'Est) pour présenter les résultats et fournir une mise à jour de l'entreprise.
Les investisseurs peuvent accéder au webcast en direct via la section 'Événements et Présentations' sur le site web des investisseurs de Moderna. La version archivée sera disponible environ deux heures après la conférence téléphonique et restera accessible pendant un an.
Moderna (NASDAQ:MRNA) hat die Bekanntgabe seiner Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 1. Mai 2025, angesetzt. Das Unternehmen wird um 8:00 Uhr ET eine Live-Konferenzschaltung und einen Webcast abhalten, um die Ergebnisse zu präsentieren und ein Unternehmensupdate zu geben.
Investoren können über den Bereich 'Veranstaltungen und Präsentationen' auf der Investoren-Website von Moderna auf den Live-Webcast zugreifen. Die archivierte Version wird etwa zwei Stunden nach der Telefonkonferenz verfügbar sein und für ein Jahr zugänglich bleiben.
- None.
- None.
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide a corporate update.
A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.
Webcast: https://investors.modernatx.com
The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Media Contacts
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Moderna (MRNA) release its Q1 2025 earnings report?
How can investors access Moderna's (MRNA) Q1 2025 earnings call?
How long will Moderna's (MRNA) Q1 2025 earnings webcast be available?
What time will Moderna's (MRNA) Q1 2025 earnings call start?
